---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-23-000026"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2023-03-10T23:59:59+00:00"
generated_at: "2026-06-18T05:16:45.124596+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Amphastar enters $0.5M amendment with related party Hanxin for insulin R&D scale-up

## Summary
- Amendment to Contract Research Agreement dated July 5, 2022 with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
- Hanxin will perform scale-up manufacturing process development using Recombinant Human Insulin Research Cell Banks (RCBs).
- Total cost not to exceed approximately $0.5 million; payments in Chinese yuan adjusted for exchange rates.
- Related party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own majority of Hanxin; Audit Committee approved.
- Agreement term matches original contract, currently through July 5, 2025.

## SEC filing metadata
- accession: 0001297184-23-000026
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2023-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/0001297184-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/amph-20230308x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-23-000026
- JSON: https://secwatch.observer/filing/0001297184-23-000026.json
- Plain text: https://secwatch.observer/filing/0001297184-23-000026.txt

## Key facts
- Material Agreements
  Amphastar Pharmaceuticals, Inc. amended Contract Research Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at not exceed approximately $0.5 million (effective 2023-03-08).
  - Action: amendment
  - Agreement: license
  - Counterparty: Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
  - Value: not exceed approximately $0.5 million
  - Effective: 2023-03-08
  source text: On March 8, 2023, Amphastar Pharmaceuticals, Inc. (together with its subsidiaries, the “Company”) and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”) entered into an Amendment to that certain Contract Research Agreement by and between the Company and Hanxin, dated July 5, 2022 (the “Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/0001297184-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.